Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.Imeglimin is a novel agent currently in development to treat type 2 diabetes.  Preliminary human studies that have been published within the last 2 years demonstrate that imeglimin improves hemoglobin A1c and fasting plasma glucose similarly when compared with metformin and with sitagliptin.  Currently, imeglimin is lacking long-term evidence to demonstrate any effects on its cardiovascular safety, and data on morbidity and mortality, though some studies are currently in progress.  There is great potential for imeglimin, if FDA approved, to play a significant role in the type 2 diabetes management algorithm.
Imeglimin
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.Imeglimin is a novel agent currently in development to treat type 2 diabetes.  Preliminary human studies that have been published within the last 2 years demonstrate that imeglimin improves hemoglobin A1c and fasting plasma glucose similarly when compared with metformin and with sitagliptin.  Currently, imeglimin is lacking long-term evidence to demonstrate any effects on its cardiovascular safety, and data on morbidity and mortality, though some studies are currently in progress.  There is great potential for imeglimin, if FDA approved, to play a significant role in the type 2 diabetes management algorithm.
Imeglimin
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.Imeglimin is a novel agent currently in development to treat type 2 diabetes.  Preliminary human studies that have been published within the last 2 years demonstrate that imeglimin improves hemoglobin A1c and fasting plasma glucose similarly when compared with metformin and with sitagliptin.  Currently, imeglimin is lacking long-term evidence to demonstrate any effects on its cardiovascular safety, and data on morbidity and mortality, though some studies are currently in progress.  There is great potential for imeglimin, if FDA approved, to play a significant role in the type 2 diabetes management algorithm.
Imeglimin
Preliminary human studies that have been published within the last 2 years demonstrate that imeglimin improves hemoglobin A1c and fasting plasma glucose similarly when compared with metformin and with sitagliptin. 
metformin
Preliminary human studies that have been published within the last 2 years demonstrate that imeglimin improves hemoglobin A1c and fasting plasma glucose similarly when compared with metformin and with sitagliptin. 
sitagliptin